Alivus Life Sciences acquires 76% stake in IQGenX Pharma

Alivus Life Sciences has acquired 76% stake in IQGenX Pharma for a consideration of Rs 9.12 crore.

Founded in October 2016, IQGenX Pharma is a custom research organization which operates in formulation development of oral solids, sterile injectable and ophthalmic solutions for US, EU, Latin America, Middle East and other highly regulated and semi regulated markets.

While APIs anchor everything that Alivus does, this acquisition enables the company to leverage its core portfolio selectively into advanced formulation development. The resultant integrated end-to-end platform will deliver deep scientific expertise across complex delivery formats, including oral solids, complex injectables and ophthalmics. Through the IQGenX platform, Alivus extends its operational footprint to include rigorous bioequivalence and stability studies, thereby enabling comprehensive regulatory filings tailored for diverse global markets. This will help significantly to expand the company's global customer base in the generic pharmaceutical segment.

Additionally, Alivus is significantly scaling up its value proposition for global CDMO customers through this expanded service platform which will cover pre-formulation studies, prototype development, process optimisation, seamless scale-up, clinical supplies and full-scale commercial manufacturing. These will be complemented with analytical development, methods validation, stability programmes and complete regulatory submission support.

Furthermore, Alivus will strategically leverage IQGenX's specialised platform alongside its own world class API portfolio, with primary focus on Oncology, to curate a high-impact basket of differentiated, niche assets. Backed by validated, commercial-scale manufacturing capabilities, these assets are primed for strategic out-licensing across multiple geographies.